A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs PF 5089771 (Primary) ; Pregabalin
- Indications Diabetic neuropathies; Pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
- 20 Nov 2014 Planned End Date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrial.gov record.
- 20 Nov 2014 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrial.gov record.